What is Cynata Therapeutics Limited?
Cynata Therapeutics Limited, together with its subsidiaries, engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
Cynata Therapeutics Limited, together with its subsidiaries, engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase 2 clinical trial for the treatment of graft versus host disease. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 85.09M.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.